NOX - Noxopharm Limited - Strawman: ASX share price, valuation, research and discussion

Top member reports

No meetings

The consensus valuation is for members only and has been removed from this chart. Click for membership options.

Become a member

Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.

Become a member

#Announcement 15/2/21

stale

Added 4 years ago

Cancer Conference Presentation Confirms Potential Breakthrough For Stage 4 Prostate Cancer Patients

• Drug combination NOX66 (Veyonda?) and 177lutetium-PSMA-617 delivers high response rates in heavily pre-treated men with end-stage prostate cancer

• Median Overall Survival of 19.7 months a potential breakthrough in the treatment of end-stage prostate cancer

Noxopharm Limited